|本期目录/Table of Contents|

[1]苏子剑,张剑华,潘群雄,等.天冬氨酸氨基转移酶血小板比值可作为肝癌经肝动脉化疗栓塞术后的预后指标[J].福建医科大学学报,2017,51(05):316-322.
 SU Zijian,ZHANG Jianhua,PAN Qunxiong,et al.Aspartate Transaminase and Platelet Ratio Index as a Prognostic Factor after Transarterial Chemoembolization for Hepatocellular Carcinoma[J].Journal of Fujian Medical University,2017,51(05):316-322.
点击复制

天冬氨酸氨基转移酶血小板比值可作为肝癌经肝动脉化疗栓塞术后的预后指标(PDF)
分享到:

《福建医科大学学报》[ISSN:1672-4194/CN:35-1192/R]

卷:
第51卷
期数:
2017年05期
页码:
316-322
栏目:
临床研究
出版日期:
2017-10-30

文章信息/Info

Title:
Aspartate Transaminase and Platelet Ratio Index as a Prognostic Factor after Transarterial Chemoembolization for Hepatocellular Carcinoma
文章编号:
16724194(2017)05031607
作者:
苏子剑 张剑华 潘群雄 王聪仁 费洪江
作者单位: 福建医科大学 附属泉州第一医院肝胆外科,泉州362000
Author(s):
SU Zijian ZHANG Jianhua PAN Qunxiong WANG Congren FEI Hongjiang
Department of Hepatobiliary Surgery, The Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China
关键词:
肝肿瘤 天冬氨酸氨基转移酶类 血小板 化学栓塞治疗性
Keywords:
KEY WORDS:liver neoplasms aspartate aminotransferases blood platelets chemoembolization therapeutic
分类号:
R331.124; R345.51; R735.7
DOI:
-
文献标志码:
A
摘要:
目的探讨天冬氨酸氨基转移酶血小板比值指数(APRI)与行经肝动脉化疗栓塞(TACE)治疗的肝癌患者的预后关系。方法回顾性分析388例肝癌患者的临床资料,根据TACE术前外周血APRI水平分为低APRI组(APRI<1.30,237例)和高APRI组(APRI≥1.30,151例),比较2组患者的1年及3年生存率。结果高APRI组的1年及3年生存率分别为25.5%和2.6%,低APRI组为71.2%和30.0%,2组间差别有统计学意义(P<0.001)。术前白蛋白及天冬氨酸氨基转移酶(AST)的水平、ChildPugh分级、肿瘤大小、脉管癌栓、APRI、TACE次数是肝癌患者术后总生存时间的独立预后因素。经ROC曲线分析比较显示,APRI较其他临床预后因素有更大的ROC曲线下面积。结论APRI可作为判断行TACE治疗的肝癌患者预后有价值的指标。
Abstract:
ABSTRACT:ObjectiveTo explore whether aspartate transaminase and platelet ratio index (APRI) is an effective prognostic marker after transarterial chemoembolization for hepatocellular carcinoma.MethodsRetrospective analysis of clinical date in 388 patients with hepatocellular carcinoma.According to preoperative APRI,the patients were divided into the low APRI group (APRI<1.30,n=237) and the high APRI group (APRI≥1.30, n=151).The 1 or 3year survival rates of the two groups were separately analyzed.ResultsThe 1year and 3year survival rates in the high APRI group were 37.3% and 19.0% respectively (P<0.01).In the low APRI group the survival rates were 57.6% and 38.2% respectively (P<0.01).The 1year and 3year recurrence rates in the high APRI group were 25.5% and 2.6% respectively (P<0.01).In the low APRI group they were 71.2% and 30.0% respectively (P<0.01).In multivariate analysis, albumin level, ChildPugh class, tumor size, vascular invasion, number of APRI, and APRI were independent predictors of hepatocellular carcinoma survival.ROC curve analysis showed that APRI had larger area under the ROC curve compared to other clinical prognostic factors.ConclusionPreoperative APRI may be a prognostic marker in patients with hepatocellular carcinoma after transarterial chemoembolization.

参考文献/References:

[1]Bosch F X, Ribes J, Clerics R, et al. Epidemiology of hepatocellular carcinoma [J].Clin Liver Dis,2005,9(2):191211.
[2]李征,米登海,杨克虎,等. 介入化疗栓塞术联合热疗治疗原发性肝癌的Meta分析[J].中国循证医学杂志,2012,12(6):672678.
[3]Llovet J M, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008[J].J Hepatol, 2008,48(1):S20S37.
[4]Rougier P, Mitry E, Barbare J C, et al. Hepatocellular carcinoma(HCC): an update[J]. Semin Oncol, 2007,34(2):S12S20.
[5]王冠军,赫捷. 肿瘤学概论[M]. 北京:人民卫生出版社, 2013:161.
[6]Tan C K, Law N M, Ng H S, et al. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation[J].J Clin Oncol,2003,21(12):22942298.
[7]Bruix J, Llovet J M. Prognostic prediction and treatment strategy in hepatocellular carcinoma[J].Hepatology, 2002,35(3):519524.
[8]Park Y H, Kim B K, Kim J K, et al. Long term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea[J].J Gastroenterol Hepatol,2014,29(5):10051011.
[9]Takayasu K, Nakanuma Y, Makuuchi M,et al.Report of the 17th nationwide followup survey of primary liver cancer in Japan[J].Hepatol Res,2007,37(9):676691.
[10]Murayama Y, Komatsu S, Shiozaki A, et al. Clinical analysis of anatomical resection for the treatment of hepatocellular carcinoma based on the stratification of liver function[J]. World J Surg, 2014,38(5):11541163.
[11]王越,刘学民,王博, 等. 术前天冬氨酸转氨酶血小板比值指数对肝细胞癌患者手术切除后并发症的预测价值[J]. 中华肝胆外科杂志, 2016,22(5):289293.
[12]Shen S L, Fu S J, Chen B, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis Binduced hepatocellular carcinoma after hepatic resection[J]. Ann Surg Oncol, 2014,21(12):3802.
[13]宋裕萍,赵擎宇,李松, 等. 非侵入性肝纤维化诊断模型对肝癌介入治疗后急性肝功能恶化的预测作用[J]. 中华医学杂志, 2016,96(9):716719.
[14]Wai C T,Greenson J K,Fontana R J,et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic C[J].Hepatology,2003,38(2):518526.
[15]Walsh N,Verster A,Rodolph M,et al. WHO guidance on the prevention of viral hepatitis B and C among people who injec drugs[J].Int J Drug Policy, 2014,25(3):363371.
[16]周霖, 王华明, 艾鼎伦,等.原发性肝癌患者肝动脉化疗栓塞术后肝功能失代偿的临床分析[J].解放军医学杂志, 2014,39(2):149153.
[17]刘金明, 张克勤, 李涛. 肝癌多次TACE术后的肝硬化分级及预后因素分析[J].实用癌症杂志,2014,29(1):6871.
[18]Zhou Y M, Sui C J, Zhang X F, et al. Influence of cirrhosis on longterm prognosis after surgery in patients with combined hepatocellularcholangio carcinoma[J].BMC Gastroenterol, 2017,17(1):25.
[19]Sasaki K, Shindoh J, Margonis G A, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma[J]. JAMA Surg, 2017,152(3):e165059.
[20]Pang Q, Zhang J Y, Xu X S,et al. The prognostic values of 12 cirrhosis relative noninvasive models in patients with hepatocellular carcinoma[J]. Scand J Clin Lab Invest, 2015,75(1):7384.
[21]Matsuo R, Nakano Y, Ohkohehi N.Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy[J]. Ann Surg, 2011,253:759763.
[22]Surtel M, Graf R, Aleil B, et al. Platelet derived serotonin mediates liver regeneration[J]. Seience, 2006,312(5770):104107.
[23]Sonohara F, Inokawa Y, Kanda M, et al. Association of inflammasome components in background liver with poor prognosis after curativelyresected hepatocellular carcinoma[J]. Anticancer Res, 2017,37(1):293300.
[24]Argiles J M, Busquets S, Toledo M, et al. The role of cytokines in cancer cachexia[J]. Curr Opin Support Palliat Care, 2009,19(3):163168.
[25]Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virusassociated cirrhosis and HCC[J]. Cancer, 1997,79(4):688694.
[26]Ji F, Fu S, Guo Z, et al. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection[J].Oncotarget, 2016,7(44):7227672289.
[27]Peng W, Li C, Wen T F, et al. Postoperative aspartate aminotransferase to platelet ratio index change predicts prognosis for hepatocellular carcinoma[J]. Medicine (Baltimore), 2016,95(30):e4160.

相似文献/References:

[1]郑智华,黄爱民,高美钦,等.APEX1单核苷酸多态性与肝癌易感性关系的研究[J].福建医科大学学报,2016,50(02):88.
 ZHENG Zhihua,HUANG Aimin,GAO Meiqin,et al.Association of Single Nucleotide Polymorphism of APEX1 Gene with Susceptibility to Hepatocellular Carcinoma[J].Journal of Fujian Medical University,2016,50(05):88.

备注/Memo

备注/Memo:
作者单位: 福建医科大学 附属泉州第一医院肝胆外科,泉州362000 作者简介: 苏子剑,男,主治医师,医学硕士. Email: 710262737@qq.com
更新日期/Last Update: 2017-10-30